178 related articles for article (PubMed ID: 15548373)
1. Exceptionally potent anti-tumor bystander activity of an scFv:sTRAIL fusion protein with specificity for EGP2 toward target antigen-negative tumor cells.
Bremer E; Samplonius D; Kroesen BJ; van Genne L; de Leij L; Helfrich W
Neoplasia; 2004; 6(5):636-45. PubMed ID: 15548373
[TBL] [Abstract][Full Text] [Related]
2. Target cell-restricted and -enhanced apoptosis induction by a scFv:sTRAIL fusion protein with specificity for the pancarcinoma-associated antigen EGP2.
Bremer E; Kuijlen J; Samplonius D; Walczak H; de Leij L; Helfrich W
Int J Cancer; 2004 Mar; 109(2):281-90. PubMed ID: 14750182
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous inhibition of epidermal growth factor receptor (EGFR) signaling and enhanced activation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-mediated apoptosis induction by an scFv:sTRAIL fusion protein with specificity for human EGFR.
Bremer E; Samplonius DF; van Genne L; Dijkstra MH; Kroesen BJ; de Leij LF; Helfrich W
J Biol Chem; 2005 Mar; 280(11):10025-33. PubMed ID: 15644326
[TBL] [Abstract][Full Text] [Related]
4. Targeted induction of apoptosis in glioblastoma multiforme cells by an MRP3-specific TRAIL fusion protein in vitro.
Wang LH; Ni CW; Lin YZ; Yin L; Jiang CB; Lv CT; Le Y; Lang Y; Zhao CY; Yang K; Jiao BH; Yin J
Tumour Biol; 2014 Feb; 35(2):1157-68. PubMed ID: 24272336
[TBL] [Abstract][Full Text] [Related]
5. Target cell-restricted apoptosis induction of acute leukemic T cells by a recombinant tumor necrosis factor-related apoptosis-inducing ligand fusion protein with specificity for human CD7.
Bremer E; Samplonius DF; Peipp M; van Genne L; Kroesen BJ; Fey GH; Gramatzki M; de Leij LF; Helfrich W
Cancer Res; 2005 Apr; 65(8):3380-8. PubMed ID: 15833872
[TBL] [Abstract][Full Text] [Related]
6. A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability.
ten Cate B; Bremer E; de Bruyn M; Bijma T; Samplonius D; Schwemmlein M; Huls G; Fey G; Helfrich W
Leukemia; 2009 Aug; 23(8):1389-97. PubMed ID: 19262596
[TBL] [Abstract][Full Text] [Related]
7. Targeted delivery of a designed sTRAIL mutant results in superior apoptotic activity towards EGFR-positive tumor cells.
Bremer E; de Bruyn M; Samplonius DF; Bijma T; ten Cate B; de Leij LF; Helfrich W
J Mol Med (Berl); 2008 Aug; 86(8):909-24. PubMed ID: 18504532
[TBL] [Abstract][Full Text] [Related]
8. Selective induction of apoptosis in leukemic B-lymphoid cells by a CD19-specific TRAIL fusion protein.
Stieglmaier J; Bremer E; Kellner C; Liebig TM; ten Cate B; Peipp M; Schulze-Koops H; Pfeiffer M; Bühring HJ; Greil J; Oduncu F; Emmerich B; Fey GH; Helfrich W
Cancer Immunol Immunother; 2008 Feb; 57(2):233-46. PubMed ID: 17665197
[TBL] [Abstract][Full Text] [Related]
9. Human umbilical cord mesenchymal stem cells as vehicles of CD20-specific TRAIL fusion protein delivery: a double-target therapy against non-Hodgkin's lymphoma.
Yan C; Li S; Li Z; Peng H; Yuan X; Jiang L; Zhang Y; Fan D; Hu X; Yang M; Xiong D
Mol Pharm; 2013 Jan; 10(1):142-51. PubMed ID: 23121392
[TBL] [Abstract][Full Text] [Related]
10. Antibody-based fusion proteins to target death receptors in cancer.
de Bruyn M; Bremer E; Helfrich W
Cancer Lett; 2013 May; 332(2):175-83. PubMed ID: 21215513
[TBL] [Abstract][Full Text] [Related]
11. Differential activation of TRAIL-R1 and -2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative.
Wajant H; Moosmayer D; Wüest T; Bartke T; Gerlach E; Schönherr U; Peters N; Scheurich P; Pfizenmaier K
Oncogene; 2001 Jul; 20(30):4101-6. PubMed ID: 11494138
[TBL] [Abstract][Full Text] [Related]
12. Tumor cell-selective apoptosis induction through targeting of K(V)10.1 via bifunctional TRAIL antibody.
Hartung F; Stühmer W; Pardo LA
Mol Cancer; 2011 Sep; 10():109. PubMed ID: 21899742
[TBL] [Abstract][Full Text] [Related]
13. The novel fusion protein sTRAIL-TMTP1 exhibits a targeted inhibition of primary tumors and metastases.
Liu R; Ma X; Wang H; Xi Y; Qian M; Yang W; Luo D; Fan L; Xia X; Zhou J; Meng L; Wang S; Ma D; Xi L
J Mol Med (Berl); 2014 Feb; 92(2):165-75. PubMed ID: 24158182
[TBL] [Abstract][Full Text] [Related]
14. Cell to cell contact required for bystander effect of the TNF-related apoptosis-inducing ligand (TRAIL) gene.
Huang X; Lin T; Gu J; Zhang L; Roth JA; Liu J; Fang B
Int J Oncol; 2003 Jun; 22(6):1241-5. PubMed ID: 12738989
[TBL] [Abstract][Full Text] [Related]
15. Potent systemic anticancer activity of adenovirally expressed EGFR-selective TRAIL fusion protein.
Bremer E; van Dam GM; de Bruyn M; van Riezen M; Dijkstra M; Kamps G; Helfrich W; Haisma H
Mol Ther; 2008 Dec; 16(12):1919-26. PubMed ID: 18813279
[TBL] [Abstract][Full Text] [Related]
16. Construction and expression of sTRAIL-melittin combining enhanced anticancer activity with antibacterial activity in Escherichia coli.
Liu H; Han Y; Fu H; Liu M; Wu J; Chen X; Zhang S; Chen Y
Appl Microbiol Biotechnol; 2013 Apr; 97(7):2877-84. PubMed ID: 23149754
[TBL] [Abstract][Full Text] [Related]
17. A bispecific fusion protein and a bifunctional enediyne-energized fusion protein consisting of TRAIL, EGFR peptide ligand, and apoprotein of lidamycin against EGFR and DR4/5 show potent antitumor activity.
Zhu D; Wang X; Shang Y; Li Y; Jiang W; Li L; Chen SZ
Anticancer Drugs; 2015 Jan; 26(1):64-73. PubMed ID: 25122444
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene.
Kagawa S; He C; Gu J; Koch P; Rha SJ; Roth JA; Curley SA; Stephens LC; Fang B
Cancer Res; 2001 Apr; 61(8):3330-8. PubMed ID: 11309289
[TBL] [Abstract][Full Text] [Related]
19. [Interleukin-12 enhanced tumor necrosis factor related apoptosis-inducing ligand TRAIL-induced apoptosis in human hepatocellular carcinoma by inhibiting expression of survivin].
He SQ; Chen Y; Chen XP; Zhang WG; Wang HP; Zhang BX
Zhonghua Wai Ke Za Zhi; 2003 Jun; 41(6):453-7. PubMed ID: 12895357
[TBL] [Abstract][Full Text] [Related]
20. DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.
Yu R; Albarenque SM; Cool RH; Quax WJ; Mohr A; Zwacka RM
Cancer Biol Ther; 2014; 15(12):1658-66. PubMed ID: 25482930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]